Robert N. Raju

1.3k total citations
30 papers, 985 citations indexed

About

Robert N. Raju is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Robert N. Raju has authored 30 papers receiving a total of 985 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Robert N. Raju's work include Lung Cancer Treatments and Mutations (8 papers), Lung Cancer Research Studies (6 papers) and HER2/EGFR in Cancer Research (6 papers). Robert N. Raju is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Lung Cancer Research Studies (6 papers) and HER2/EGFR in Cancer Research (6 papers). Robert N. Raju collaborates with scholars based in United States, Canada and United Kingdom. Robert N. Raju's co-authors include Lina Asmar, D. Ilegbodu, Kathy S. Albain, Melody Cobleigh, David Loesch, Robert J. Belt, Brian Leyland‐Jones, Lea Fuchs, Robert M. Sayre and Elizabeth Valentine and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Robert N. Raju

30 papers receiving 966 citations

Peers

Robert N. Raju
Dina Leitão Portugal
Elizabeth Crowley United States
Yasuyo Ohi Japan
Lorenza Pistola Italy
Anastasia G Eleftheraki Greece
Huiying Piao United States
H. A. Burris United States
Xiaopei Zhu United States
N. Gabrail United States
Colm Hennessy United Kingdom
Dina Leitão Portugal
Robert N. Raju
Citations per year, relative to Robert N. Raju Robert N. Raju (= 1×) peers Dina Leitão

Countries citing papers authored by Robert N. Raju

Since Specialization
Citations

This map shows the geographic impact of Robert N. Raju's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert N. Raju with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert N. Raju more than expected).

Fields of papers citing papers by Robert N. Raju

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert N. Raju. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert N. Raju. The network helps show where Robert N. Raju may publish in the future.

Co-authorship network of co-authors of Robert N. Raju

This figure shows the co-authorship network connecting the top 25 collaborators of Robert N. Raju. A scholar is included among the top collaborators of Robert N. Raju based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert N. Raju. Robert N. Raju is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Friedberg, Jonathan W., Joseph M. Unger, Richard Burack, et al.. (2014). R‐CHOPwith iodine‐131 tositumomab consolidation for advanced stage diffuse largeB‐cell lymphoma (DLBCL):SWOG S0433. British Journal of Haematology. 166(3). 382–389. 24 indexed citations
2.
Cohn, Allen Lee, Michael Lahn, Ann Cleverly, et al.. (2014). A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer. International Journal of Oncology. 45(6). 2221–2231. 37 indexed citations
3.
Richards, Donald, Fadi S. Braiteh, Agustin A. García, et al.. (2014). A phase 1 study of MM-111, a bispecific HER2/HER3 antibody fusion protein, combined with multiple treatment regimens in patients with advanced HER2-positive solid tumors.. Journal of Clinical Oncology. 32(15_suppl). 651–651. 33 indexed citations
4.
5.
Weiss, Glen J., Winnie S. Liang, Tyler Izatt, et al.. (2012). Paired Tumor and Normal Whole Genome Sequencing of Metastatic Olfactory Neuroblastoma. PLoS ONE. 7(5). e37029–e37029. 28 indexed citations
6.
Cunningham, Charles, Neil Senzer, Donald Richards, et al.. (2009). Phase II Trial of Talabostat and Docetaxel in Advanced Non-small Cell Lung Cancer. Clinical Oncology. 21(6). 464–472. 75 indexed citations
7.
8.
Socinski, Mark A., Robert N. Raju, Marcus A. Neubauer, et al.. (2008). Pemetrexed in Relapsed Small-Cell Lung Cancer and the Impact of Shortened Vitamin Supplementation Lead-In Time: Results of a Phase II Trial. Journal of Thoracic Oncology. 3(11). 1308–1316. 20 indexed citations
9.
Hutson, Thomas E., Svetislava J. Vukelja, Daniel Atienza, et al.. (2008). Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium. Investigational New Drugs. 26(2). 151–158. 4 indexed citations
10.
Socinski, Mark A., Robert N. Raju, Donald Richards, et al.. (2007). P1-229: The impact of shortened vitamin supplementation lead-in time before pemetrexed (P) in patients with relapsed small-cell lung cancer (SCLC). Journal of Thoracic Oncology. 2(8). S829–S830. 1 indexed citations
11.
Raju, Robert N., Marcus A. Neubauer, Deborah A. Smith, et al.. (2007). Pemetrexed (P) in relapsed small cell lung cancer (SCLC): Preliminary results of a phase II trial. Journal of Clinical Oncology. 25(18_suppl). 7716–7716. 5 indexed citations
12.
Robert, Nicholas J., Brian Leyland‐Jones, Lina Asmar, et al.. (2006). Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2–Overexpressing Metastatic Breast Cancer. Journal of Clinical Oncology. 24(18). 2786–2792. 342 indexed citations
13.
Neubauer, Marcus A., David Garfield, Robert N. Raju, et al.. (2004). Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer. Lung Cancer. 47(1). 121–127. 15 indexed citations
14.
Robert, N. J., Brian Leyland‐Jones, Lina Asmar, et al.. (2004). Randomized phase III study of trastuzumab, paclitaxel, and carboplatin versus trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer: An update including survival. Journal of Clinical Oncology. 22(14_suppl). 573–573. 28 indexed citations
15.
Shackney, Stanley E., Reginald P. Pugh, Bernard L. Zidar, et al.. (1990). ViVACCy—A Drug Schedule Based on G2 Blockade and Prolonged Infusion of Multiple Tubulin-Binding Agents A Pilot Study. Cancer. 66(3). 411–417. 1 indexed citations
16.
Zidar, Bernard L., George J. Magovern, Robert N. Raju, et al.. (1987). Radiation-induced leiomyosarcoma of the great vessels presenting as superior vena cava syndrome. Cancer. 60(6). 1238–1242. 18 indexed citations
17.
Zidar, Bernard L., Robert J. Hartsock, Robert Lee, et al.. (1987). Pseudo-Gaucher Cells in the Bone Marrow of a Patient with Hodgkin’s Disease. American Journal of Clinical Pathology. 87(4). 533–536. 31 indexed citations
18.
Zidar, Bernard L., et al.. (1983). Treatment of six cases of mesothelioma with doxorubicin and cisplatin. Cancer. 52(10). 1788–1791. 33 indexed citations
19.
Kardinal, Carl G., Michael C. Perry, Vivian Weinberg, et al.. (1983). Chemoendocrine therapy vs chemotherapy alone for advanced breast cancer in postmenopausal women: Preliminary report of a randomized study. Breast Cancer Research and Treatment. 3(4). 365–371. 21 indexed citations
20.
Raju, Robert N., et al.. (1983). Lactic Acidosis in Lung Cancer. Southern Medical Journal. 76(3). 397–398. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dina Leitão Breakdown of academic impact, for papers by Elizabeth Crowley Breakdown of academic impact, for papers by Yasuyo Ohi Breakdown of academic impact, for papers by Lorenza Pistola Breakdown of academic impact, for papers by Anastasia G Eleftheraki Breakdown of academic impact, for papers by Huiying Piao Breakdown of academic impact, for papers by H. A. Burris Breakdown of academic impact, for papers by Xiaopei Zhu Breakdown of academic impact, for papers by N. Gabrail Breakdown of academic impact, for papers by Colm Hennessy
Rankless by CCL
2026